Horvat, T.Z. (2015) Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients with Melanoma Treated with Ipilimumab at Memorial Sloan Kettering Cancer Center. Journal of Clinical Oncology, 33, 3193-3198.
https://doi.org/10.1200/JCO.2015.60.8448

has been cited by the following article:

• TITLE: Successful Combination Therapy of Nivolumab and Radiation for Massive Mucosal Melanoma in Patient with Autoimmune-Myasthenia Gravis, Systemic Lupus Erythematosus and Rheumatoid Arthritis

  AUTHORS: Asako Ota, Atsushi Tanemura, Reika Aoyama, Yorihisa Kotobuki, Keita Kakuta, Kohei Tsujimoto, Toshiro Tanaka, Shigeaki Suzuki, Ichiro Katayama

  KEYWORDS: Anti PD-1 Antibody, Radiation, Malignant Melanoma, Myasthenia Gravis

  JOURNAL NAME: Journal of Cosmetics, Dermatological Sciences and Applications, Vol.8 No.1, March 23, 2018

  ABSTRACT: A 58-year-old woman complicated with autoimmune diseases of myasthenia gravis (MG), rheumatoid arthritis, and systemic lupus erythematosus noticed an irregular black macule on her bilateral major labia, which was diagnosed as malignant melanoma. The melanoma lesion involving the vagina, uterus, and ventral side of rectum was not operable and was treated with nivolumab and concurrent radiotherapy with good control of the MG. This resulted in remarkable tumor shrinkage, possibly due to synergistic effects of both treatments. To our knowledge, few reports have described the effectiveness of combination therapy with nivolumab and radiation for malignant melanoma. The present case showed an enhanced anti-tumor effect with combination therapy.